tbuckley/cabot-search huggingface dataset:
Tussive challenge with ATP and AMP: does it reveal cough hypersensitivity?
Authors: Helen Elizabeth Fowles, Tim Rowland, Caroline Wright, Alyn Morice
Journal: European Respiratory Journal (2017)

Recent studies have demonstrated that blockade of P2X3 ATP receptors can profoundly inhibit chronic cough. We have considered whether inhaled ATP produces a tussive response and whether chronic cough patients are hypersensitive to inhaled ATP compared to healthy volunteers. A standardised inhalational cough challenge was performed with ATP and AMP. We randomised 20 healthy volunteers and 20 chronic cough patients as to the order of challenges. The concentration of challenge solution causing at least five coughs (C5) was compared for ATP and AMP. The study population consisted of six male and 14 female volunteers in each group. Two out of 19 healthy volunteers coughed with AMP (one volunteer could not take part in this challenge) and none reached C5. Eight out of 20 chronic cough patients coughed with AMP and two reached C5. Of the 20 healthy volunteers, 18 coughed with ATP, with 15 reaching C5. All 19 chronic cough patients completing the ATP challenge coughed with ATP and 18 reached C5. The chronic cough patients had a greater cough response at lower concentrations of ATP. The greater potency of ATP versus AMP in the inhalational challenge suggests that tussive responses are mediated through members of the P2X purinergic receptor family. This acute effect was, however, not sufficient to explain cough hypersensitivity syndrome.
Erratum: Corrigendum: Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes
Authors: Jenny Aurielle B Babon, Megan E DeNicola, David M Blodgett, Inne Crèvecoeur, Thomas S Buttrick, René Maehr, Rita Bottino, Ali Naji, John Kaddis, Wassim Elyaman, Eddie A James, Rachana Haliyur, Marcela Brissova, Lut Overbergh, Chantal Mathieu, Thomas Delong, Kathryn Haskins, Alberto Pugliese, Martha Campbell-Thompson, Clayton Mathews, Mark A Atkinson, Alvin C Powers, David M Harlan, Sally C Kent
Journal: Nature Medicine (2017)
Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043)
Authors: C. Mackall, S. D'Angelo, S. Grupp, J. Glod, M. Druta, W. Chow, K. Chagin, M. Mehler, G. Kari, T. Trivedi, T. Holdich, L. Pandite, R. Amado
Journal: Annals of Oncology (2016)
Multicenter Phase II Clinical Trial of Nilotinib for Patients with Imatinib-Resistant or Intolerant CML From the East Japan CML Study Group (EJCML) Trial: Evaluation of Molecular Responses by the BCR-ABL1 Mutational Status and Plasma Trough Concentration of Nilotinib
Authors: Naoto Takahashi, Masatomo Miura, Jun Kuroki, Kinuko Mitani, Atsushi Kitabayashi, Osamu Sasaki, Hideo Kimura, Kiyotoshi Imai, Norifumi Tsukamoto, Hideyoshi Noji, Takeshi Kondo, Akihisa Kuwayama, Mutsuhito Motegi, Yuichi Kato, Kaoru Takahashi, Masayuki Mita, Hajime Saito, Chikashi Yoshida, Yoshihiro Torimoto, Tomofumi Kimura, Yuji Wano, Jun Nomura, Satoshi Yamamoto, Ko Mayama, Riko Honma, Tomohiro Sugawara, Shinji Sato, Atsushi Shinagawa, Akihiko Chubachi, Hideo Harigae, Kenichi Sawada
Journal: Blood (2012)
Cost-Effectiveness Analysis of a “Just-In-Time” Strategy of Salvage Plerixafor Administration for Poor-Mobilizing Patients Undergoing Autologous Transplant
Authors: Jie Li, Ellie Hamilton, Louette Vaughn, Michael Graiser, Heather Renfroe, Jonathan L. Kaufman, Sagar Lonial, Christopher R Flowers, Mary Jo Lechowicz, Amelia Langston, Darlene Anderson, Edmund Waller
Journal: Blood (2010)
PTPN11 and RAS Gene Mutation Pattern Identifies an Unique Feature of Upregulated RAS Function in Infant ALL.
Authors: Giovanni Cazzaniga, Simone Martinelli, Monique L. den Boer, Lilia Corral, Monica Spinelli, Giuseppe Basso, Giulio De Rossi, Rob Pieters, Marco Tartaglia, Andrea Biondi
Journal: Blood (2004)
Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.
Authors: Mamta Gupta, Mary Stenson, Terra Lasho, Ayalew Tefferi, Anne Novak, Stephen M. Ansell, Thomas E. Witzig
Journal: Blood (2009)
Emergence of the lymphogranuloma venereum L2c genovariant, Hungary, 2012 to 2016
Authors: Fruzsina Petrovay, Eszter Balla, Tímea Erdősi
Journal: Eurosurveillance (2017)

In eastern Europe, few countries have so far reported laboratory-confirmed cases of lymphogranuloma venereum (LGV). Here we describe 22 LGV cases in men who have sex with men (MSM) detected in Hungary from November 2012 to July 2016. Sequence analyses show that 16 of these 22 cases were affected by the L2c genovariant, with from 2012 to 2014, one LGV L2c case detected per year, followed by seven cases in 2015 and six up to July 2016. Of the 16 total L2c LGV cases, 10 had severe haemorrhagic proctitis. These findings are concerning as cases with this new genovariant among MSM have not been frequently reported in Europe to date. More research is needed to assess the spread of the L2c genovariant and its potential association with virulence and severe clinical manifestation.
208P Significance of the difference in size of liver tumors in management of patients with colorectal liver metastases
Authors: K. Ichida, K. Suzuki, Y. Muto, T. Fukui, Y. Takayama, K. Futsuhara, S. Tsujinaka, Y. Miyakura, H. Noda, T. Rikiyama
Journal: Annals of Oncology (2016)
511P Retrospective study of sarcoma in practical and developmental therapeutics in Japan
Authors: T. Nishikawa, K. Yonemori, A. Kitano, T. Shimoi, E. Noguchi, M. Yunokawa, C. Shimizu, Y. Fujiwara, A. Yoshida, E. Kobayashi, F. Nakatani, A. Kawai, H. Chuman, T. Koyama, A. Shimomura, S. Kitano, T. Shimizu, Y. Fujiwara, N. Yamamoto, K. Tamura
Journal: Annals of Oncology (2016)
Asp299Gly Polymorphism of the TLR-4 Gene in Adult Patients with Fixed and with Reversible Airflow Obstruction in the Population of Crimea, Ukraine
Authors: Yuriy Bisyuk, A. Kurchenko, O. Akhtemiichuk, A. Dubovyi, Lawrence M. DuBuske
Journal: Journal of Allergy and Clinical Immunology (2017)
P08.67 Inhibition of MutT homolog 1 (MTH1) in glioblastoma multiforme results in impaired cell migration and tumor growth
Authors: M. Timmer, S. Kannampuzha
Journal: Neuro-Oncology (2016)

AbstractIntroduction:MutT homolog1 (MTH1) is required for survival of cancer cells. These have irregular redox formation resulting in the production of reactive oxygen species which damage the deoxynucleoside triphosphate pool and subsequent the DNA. MTH1 plays a crucial role by inhibiting the incorporation of oxidized bases into the DNA that avoid apoptosis of cancer cells. Our aim was to analyze the pathophysiological role of MTH1 in glioma.Materials and methods:MTH1 expression was analyzed in human glioma specimens by quantitative RT-PCR, immunohistochemistry and Western Blot. U87 cell migration in vitro and tumor growth in an orthotopic rat model was monitored after knock-down of MTH1 by siRNA or inhibition by crizotinib. In addition, progression free survival of patients was correlated to the MTH1 level.Results:Higher expression of MTH1 was observed in glioblastoma than in lower grade astrocytomas (p<0.05) and peritumoral tissue, both, on the gene and protein level. MTH1 siRNA transfected U87 cells showed slower migration compared to control U87 cells (p<0.01). Furthermore, treatment with crizotinib, an inhibitor of MTH1, also lowered cell migration. In rats, tumor growth was significantly impaired in MTH1 siRNA U87 grafts (p<0.01).Discussion:These results show that MTH1 might play an essential role in both, malignization of glioma and disease progression in recurrent glioblastoma. Moreover, the MTH1 level in patients seems to influence tumor growth and could be targeted by crizotinib indicating a role for potential future therapies.
Ki23819 (KRN383•HCl) Inhibits Kinase Activity of Wild Type and Mutant FLT3 Receptor Tyrosine Kinase In Vitro.
Authors: Yukiko Komeno, Mineo Kurokawa, Yoichi Imai, Masataka Takeshita, Tomoko Matsumura, Kazuo Kubo, Tetsuya Yoshino, Uichi Nishiyama, Tomoaki Kuwaki, Kinya Kubo, Tatsushi Osawa, Seishi Ogawa, Shigeru Chiba, Atsushi Miwa, Hisamaru Hirai
Journal: Blood (2004)
Successful Pretreatment with Omalizumab in Anaphylactic Shock Caused By Bee Venom Immunotherapy
Authors: Arturo Ruiz San Francisco, Carmen Rondon Segovia, Oliver Muñoz Daga, Ana Molina, Maria Dolores Cañamero, Cristobalina Mayorga, Maria J. Torres
Journal: Journal of Allergy and Clinical Immunology (2017)
Interleukin-1 Drives Precocious Myeloid Differentiation of Hematopoietic Stem Cells at the Expense of Self-Renewal
Authors: Eric Martin Pietras, Cristina Mirantes-Barbeito, Sarah Fong, Dirk Loffler, Larisa Vladimirovna Kovtonyuk, Ranjani Lakshminarashimhan, Chih Peng Chin, Jose-Marc Techner, Britta Will, Claus Nerlov, Ulrich Steidl, Markus Manz, Timm Schroeder, Emmanuelle Passegue
Journal: Blood (2015)
Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer
Authors: Hannah Carter, Rachel Marty, Matan Hofree, Andrew M. Gross, James Jensen, Kathleen M. Fisch, Xingyu Wu, Christopher DeBoever, Eric L. Van Nostrand, Yan Song, Emily Wheeler, Jason F. Kreisberg, Scott M. Lippman, Gene W. Yeo, J. Silvio Gutkind, Trey Ideker
Journal: Cancer Discovery (2017)

Recent studies have characterized the extensive somatic alterations that arise during cancer. However, the somatic evolution of a tumor may be significantly affected by inherited polymorphisms carried in the germline. Here, we analyze genomic data for 5,954 tumors to reveal and systematically validate 412 genetic interactions between germline polymorphisms and major somatic events, including tumor formation in specific tissues and alteration of specific cancer genes. Among germline-somatic interactions, we found germline variants in RBFOX1 that increased incidence of SF3B1 somatic mutation by 8-fold via functional alterations in RNA splicing. Similarly, 19p13.3 variants were associated with a 4-fold increased likelihood of somatic mutations in PTEN. In support of this association, we found that PTEN knockdown sensitizes the MTOR pathway to high expression of the 19p13.3 gene GNA11 Finally, we observed that stratifying patients by germline polymorphisms exposed distinct somatic mutation landscapes, implicating new cancer genes. This study creates a validated resource of inherited variants that govern where and how cancer develops, opening avenues for prevention research.Significance: This study systematically identifies germline variants that directly affect tumor evolution, either by dramatically increasing alteration frequency of specific cancer genes or by influencing the site where a tumor develops. Cancer Discovery; 7(4); 410-23. ©2017 AACR.See related commentary by Geeleher and Huang, p. 354This article is highlighted in the In This Issue feature, p. 339.
Complementary systems: Quality and timeliness of passive vs. active adverse event reporting and regulatory vs. peer-reviewed adverse drug reaction (ADR) dissemination
Authors: C. L. Bennett, C. Angelotta, A. J. Lurie, E. A. Lyons, P. R. Yarnold, D. W. Raisch
Journal: Journal of Clinical Oncology (2006)

6062 Background: RADAR, a NIH funded R01 project, obtains reports of serious ADRs by conducting hypothesis-driven active surveillance efforts in hematology/oncology. The FDA and pharmaceutical sponsors conduct passive surveillance efforts based on review of reports voluntarily submitted by health care workers. Methods: Completeness and timeliness of ADR reports and dissemination efforts by RADAR versus the FDA/pharmaceutical sponsors were compared. Results: Individual reports were more complete in RADAR databases with fewer total reports (341 versus 1,341). Pharmaceutical sponsors disseminated ADR data 1 year (median) earlier as revised package inserts (PIs), but RADAR publications were more complete. Conclusion: Compared to pharmacovigilance efforts by the FDA/pharmaceutical suppliers, RADAR is more complete but less timely. [Table: see text] No significant financial relationships to disclose.
Impact of Safety Concerns of Erythropoiesis-Stimulating Agents (ESAs) and Regulatory Changes on the Use of ESAs and Red Blood Cell (RBC) Transfusions at a Comprehensive Cancer Center
Authors: Saroj Vadhan-Raj, Victoria E. Hawkins, Xiao Zhou, Kurt Sizer, Lincy S. Lal, Joyce Roquemore, Rebecca B. Arbuckle, Robert S. Benjamin, Benjamin Lichtiger
Journal: Blood (2008)
Regulation of the Asthma-Associated Genes GSDMB and ORMDL3 Is Primarily Determined By Genotype That Is Mediated through DNA Methylation
Authors: Parul H. Kothari, Weiliang Qiu, Damien C. Croteau-Chonka, Vincent J. Carey, Benjamin A. Raby
Journal: Journal of Allergy and Clinical Immunology (2017)
HOX-Gene Expression and Inhibition of the Non-Canonical NF-KappaB Pathway in t(7;12) Leukemias
Authors: Sarah Wildenhain, Julia Hauer, Silija Roettgers, Hartmut Engelmann, Astrid Novosel, Vera Binder, Robert K. Slany, Wolf-Dieter Ludwig, Jochen Harbott, Arndt Borkhardt
Journal: Blood (2008)
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
Authors: Marcello Tiseo, Luca Boni, Francesca Ambrosio, Andrea Camerini, Editta Baldini, Saverio Cinieri, Matteo Brighenti, Francesca Zanelli, Efisio Defraia, Rita Chiari, Claudio Dazzi, Carmelo Tibaldi, Gianni Michele Turolla, Vito D’Alessandro, Nicoletta Zilembo, Anna Rita Trolese, Francesco Grossi, Ferdinando Riccardi, Andrea Ardizzoni
Journal: Journal of Clinical Oncology (2017)

Purpose Considering promising results in phase II studies, a randomized phase III trial was designed to assess the efficacy of adding bevacizumab to first-line cisplatin plus etoposide for treatment of extensive-disease (ED) small-cell lung cancer (SCLC). Patients and Methods Treatment-naive patients with ED-SCLC were randomly assigned to receive either cisplatin plus etoposide (arm A) or the same regimen with bevacizumab (arm B) for a maximum of six courses. In the absence of progression, patients in arm B continued bevacizumab alone until disease progression or for a maximum of 18 courses. The primary end point was overall survival (OS). Results Two hundred four patients were randomly assigned and considered in intent-to-treat analyses (103 patients in arm A and 101 patients in arm B). At a median follow-up of 34.9 months in arm A and arm B, median OS times were 8.9 and 9.8 months, and 1-year survival rates were 25% and 37% (hazard ratio, 0.78; 95% CI, 0.58 to 1.06; P = .113), respectively. A statistically significant effect of bevacizumab on OS in patients who received maintenance was seen (hazard ratio, 0.60; 95% CI, 0.40 to 0.91; P = .011). Median progression-free survival times were 5.7 and 6.7 months in arm A and arm B, respectively ( P = .030). Regarding hematologic toxicity, no statistically significant differences were observed; for nonhematologic toxicity, only hypertension was more frequent in arm B (grade 3 or 4, 1.0% v 6.3% in arms A v B, respectively; P = .057). Conclusion The addition of bevacizumab to cisplatin and etoposide in the first-line treatment of ED-SCLC had an acceptable toxicity profile and led to a statistically significant improvement in progression-free survival, which, however, did not translate into a statistically significant increase in OS. Further research with novel antiangiogenic agents, particularly in the maintenance setting, is warranted.
Haploidentical Allogeneic Versus Gene Modified Autologous Stem Cell Transplantation for Severe Combined Immunodeficiencies (S.C.I.D). The Risk/Benefit Balance Is in Favor of Gene Therapy.
Authors: Marina Cavazzana-Calvo, Salima Hacein-Bey-Abina, Genevieve Saint-Basile, Françoise Le Deist, Nicolas Wulfraat, Ian Alexander, Paul Landais, Stephane Blanche, Alain Fischer
Journal: Blood (2004)
Timing of the survivorship visit and symptom prevalence in breast cancer survivors.
Authors: Halle C. F. Moore, Moaath Khader Mustafa Ali, Machelle Moeller, Lisa A. Rybicki
Journal: Journal of Clinical Oncology (2016)

125 Background: Since 2009, breast cancer patients at the Cleveland Clinic have been offered Survivorship Visits during which treatment summaries and follow-up care plans are provided following a detailed assessment of patient reported concerns. Timing of the initial Survivorship Visit varied from within 6 months of to more than 5 years from completing initial therapy. It is hypothesized that survivorship needs will differ between early, middle and late survivorship periods. Methods: Through an IRB approved data base, we evaluated symptom prevalence among women treated for stage 0 to III breast cancer according to treatment received and by time interval between completion of initial treatment and the first formal Survivorship Visit. Time intervals were divided into early (within 6 months), middle (more than 6 months but less than 5 years) or late (5 years or more) survivorship periods with respect to completion date of local therapy and any chemotherapy. Symptom prevalence was compared among the three time intervals using the Chi-square test. Results: Between April 2009 and August 2015, 1257 patients received formal initial Survivorship Visits with completion of a survivorship questionnaire. Detailed results of patient reported rates of fatigue, pain, numbness, concentration difficulty, anxiety, depression, hot flashes, insomnia and sexual problems will be described during the three different survivorship periods (early, middle , and late). Conclusions: Understanding of patient reported concerns at various time points during cancer survivorship should allow for better tailoring of survivorship needs and services.
A New Approach Identifies a Previously Unrecognized and Dominant Population of Human Type-2 Innate Lymphoid Cells (ILC2s)
Authors: Mukesh Verma, Sucai Liu, Lidia Michalec, Anand Sripada, Donald Rollins, James Good, Magdalena M. Gorska, Rafeul Alam
Journal: Journal of Allergy and Clinical Immunology (2017)
Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry
Authors: Benedetto Bruno, Roberto Passera, Francesca Patriarca, Francesca Bonifazi, Vittorio Montefusco, Michele Falda, Luisa Giaccone, Mauro Montanari, Andrea Bacigalupo, Stefano Guidi, Nicola Mordini, Alessandro Rambaldi, Giuseppe Milone, Angelo Michele Carella, Pasqua Bavaro, Fabio Ciceri, Rosanna Scimè, Eduardo Benedetti, Alessandro Levis, Paola Marenco, Marco Casini, Alberto Bosi, Paolo Corradini, Giuseppe Bandini, Renato Fanin, Mario Boccadoro, Simona Pollichieni
Journal: Blood (2011)
Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02
Authors: B. Pérez-Valderrama, A. Font, J.A. Virizuela Echaburu, S. Hernando, M.A. Climent, J. Arranz Arija, J.C. Villa Guzman, M. Llorente, N. Lainez Milagro, B. Mellado, A. González del Alba, E. Gallardo, D. Castellano, U. Anido, M. Domenech, X. Garcia del Muro, J. Puente, R. Morales, J. Bellmunt, J. Garcia-Donas
Journal: Annals of Oncology (2016)
Feasibility and preliminary efficacy of an interactive portal for lung cancer patients.
Authors: Wim G Groen, Wilma Kuijpers, Hester SA Oldenburg, Michel W.J.M. Wouters, Neil K Aaronson, Wim H van Harten
Journal: Journal of Clinical Oncology (2016)

201 Background: “MijnAVL” is an interactive portal for cancer patients that includes patient education, an overview of appointments, access to the electronic medical record, patient-reported outcomes and related feedback, and tailored physical activity support. The aim of this study was to evaluate MijnAVL’s feasibility and preliminary efficacy among lung cancer patients. Methods: We included individuals currently or recently treated for lung cancer with curative intent (surgery or radiotherapy). At baseline, they completed a questionnaire on sociodemographics, expectations of MijnAVL and three effect measures: patient activation (PAM), quality of life (SF-36), and physical activity (IPAQ). MijnAVL could be used noncommittally for 4 months. After this period, log data were collected retrospectively and participants completed questions on satisfaction and the effect measures. Results: We included 37 patients (mean age 59.6 years). The mean number of logins was 11.2 with a mean duration of 12.9 minutes. Eighty-nine percent of patients indicated that MijnAVL was easy to use and 82% was positive about using it. Many patients (69%) indicated that MijnAVL was a valuable addition to the care they received and 56% indicated that it helped them to have more control over their health. All features were frequently used and rated 7 or higher on a 10 point scale. Website user satisfaction was rated, on average, 3.9 on a 5 point scale. Patient activation decreased over time from 64.8 to 59.4 (p= 0.049), meaning patients felt less activated. For the SF-36, we found no significant changes over time. In general, levels of physical activity did not change, although vigorous physical activity tended to increase over time (from median of 0 to 360 MET-minutes per week (p= .053)). Conclusions: These results indicate that using MijnAVL is feasible in lung cancer patients. Most users indicated that MijnAVL was useful and easy to use. The efficacy of the patient portal could not be substantiated, which could be due to small sample size, the intervention itself, the (insensitivity of) outcome measures, or a combination of these. Further research is needed to find effective ways to improve and adequately measure patient empowerment in lung cancer survivors.
236P Comparing chemo-radiotherapy with 5-fluorouracil and cisplatin versus thoracoscopic esophagectomy for cStage II- III esophageal squamous cell carcinoma
Authors: T. Kashiwada, Y. Harada, Y. Yoda, H. Noshiro, N. Aragane, S. Kimura
Journal: Annals of Oncology (2016)
Aligned Nanofibrous Cell‐Derived Extracellular Matrix for Anisotropic Vascular Graft Construction
Authors: Qi Xing, Zichen Qian, Mitchell Tahtinen, Ai Hui Yap, Keegan Yates, Feng Zhao
Journal: Advanced Healthcare Materials (2017)

There is a large demand for tissue engineered vascular grafts for the application of vascular reconstruction surgery or in vitro drug screening tissue model. The extracellular matrix (ECM) composition along with the structural and mechanical anisotropy of native blood vessels is critical to their functional performance. The objective of this study is to develop a biomimetic vascular graft recapitulating the anisotropic features of native blood vessels by employing nanofibrous aligned fibroblast-derived ECM and human mesenchymal stem cells (hMSCs). The nanotopographic cues of aligned ECM direct the initial cell orientation. The subsequent maturation under circumferential stress generated by a rotating wall vessel (RWV) bioreactor further promotes anisotropic structural and mechanical properties in the graft. The circumferential tensile strength is significantly higher than longitudinal strength in bioreactor samples. Expression of smooth muscle cell specific genes, α-smooth muscle actin and calponin, in hMSCs is greatly enhanced in bioreactor samples without any biochemical stimulation. In addition, employment of premade ECM and RWV bioreactor significantly reduces the graft fabrication time to three weeks. Mimicking the ECM composition, cell phenotype, structural and mechanical anisotropy, the vascular graft presented in this study is promising for vascular reconstruction surgery or in vitro tissue model applications.